NCT03854227: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

NCT03854227
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active uncontrolled or symptomatic CNS metastases
https://ClinicalTrials.gov/show/NCT03854227

Comments are closed.

Up ↑